---
figid: PMC9710321__mca-0005-0207-g01
pmcid: PMC9710321
image_filename: mca-0005-0207-g01.jpg
figure_link: /pmc/articles/PMC9710321/figure/F1/
number: Fig. 1
figure_title: ''
caption: Main molecular targets for cannabidiol (CBD) in Parkinson's disease (PD).
  Cannabinoid receptors (CB1/CB2), transient receptor potential cation channel subfamily
  V member 1 (TRPV1), Wnt/GSK-3β (Wnt/glycogen synthase kinase 3 beta pathway), nerve
  growth factor (NGF), neurotrophic tyrosine kinase receptor member (TrkA), Janus
  kinase (JAK), signal transducer and activator of transcription proteins (SATAxin3),
  nicotinamide adenine dinucleotide (NADH), adenomatous polyposis coli (APC), casein
  kinase 1 (CK1), beta-catenin (β-catenin), nuclear factor kappa-light-chain-enhancer
  of activated B cells (NF-κB).
article_title: 'Cannabis sativa and Cannabidiol: A Therapeutic Strategy for the Treatment
  of Neurodegenerative Diseases?.'
citation: Milena de Barros Viana, et al. Med Cannabis Cannabinoids. 2022 Jan-Dec;5(1):207-219.
year: '2022'

doi: 10.1159/000527335
journal_title: Medical Cannabis and Cannabinoids
journal_nlm_ta: Med Cannabis Cannabinoids
publisher_name: S. Karger AG

keywords:
- Cannabis sativa
- Cannabidiol
- Neurodegeneration
- Neuroprotection

---
